161 related articles for article (PubMed ID: 16380618)
1. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria.
de Seze J; Lanctin C; Lebrun C; Malikova I; Papeix C; Wiertlewski S; Pelletier J; Gout O; Clerc C; Moreau C; Defer G; Edan G; Dubas F; Vermersch P
Neurology; 2005 Dec; 65(12):1950-3. PubMed ID: 16380618
[TBL] [Abstract][Full Text] [Related]
2. Dengue-associated longitudinally extensive transverse myelitis.
Kumar N; Mishra R; Bargali A; Bhavana RI
BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38531558
[TBL] [Abstract][Full Text] [Related]
3. Transverse myelitis: a diagnostic challenge.
Abkur T; Saeed M
Clin Med (Lond); 2021 Nov; 21(6):e682. PubMed ID: 34862236
[No Abstract] [Full Text] [Related]
4. Transverse myelitis.
Beh SC; Greenberg BM; Frohman T; Frohman EM
Neurol Clin; 2013 Feb; 31(1):79-138. PubMed ID: 23186897
[TBL] [Abstract][Full Text] [Related]
5. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
West TW; Hess C; Cree BA
Semin Neurol; 2012 Apr; 32(2):97-113. PubMed ID: 22961185
[TBL] [Abstract][Full Text] [Related]
6. Acute transverse myelitis: a practical reappraisal.
Sá MJ
Autoimmun Rev; 2009 Dec; 9(2):128-31. PubMed ID: 19389491
[TBL] [Abstract][Full Text] [Related]
7. Transverse myelitis--a review of the presentation, diagnosis, and initial management.
West TW
Discov Med; 2013 Oct; 16(88):167-77. PubMed ID: 24099672
[TBL] [Abstract][Full Text] [Related]
8. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.
Outteryck O; Ongagna JC; Brochet B; Rumbach L; Lebrun-Frenay C; Debouverie M; Zéphir H; Ouallet JC; Berger E; Cohen M; Pittion S; Laplaud D; Wiertlewski S; Cabre P; Pelletier J; Rico A; Defer G; Derache N; Camu W; Thouvenot E; Moreau T; Fromont A; Tourbah A; Labauge P; Castelnovo G; Clavelou P; Casez O; Hautecoeur P; Papeix C; Lubetzki C; Fontaine B; Couturier N; Bohossian N; Clanet M; Vermersch P; de Sèze J; Brassat D; ;
Eur J Neurol; 2014; 21(1):40-8. PubMed ID: 23895407
[TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica in France: a multicenter study of 125 patients.
Collongues N; Marignier R; Zéphir H; Papeix C; Blanc F; Ritleng C; Tchikviladzé M; Outteryck O; Vukusic S; Fleury M; Fontaine B; Brassat D; Clanet M; Milh M; Pelletier J; Audoin B; Ruet A; Lebrun-Frenay C; Thouvenot E; Camu W; Debouverie M; Créange A; Moreau T; Labauge P; Castelnovo G; Edan G; Le Page E; Defer G; Barroso B; Heinzlef O; Gout O; Rodriguez D; Wiertlewski S; Laplaud D; Borgel F; Tourniaire P; Grimaud J; Brochet B; Vermersch P; Confavreux C; de Seze J
Neurology; 2010 Mar; 74(9):736-42. PubMed ID: 20194912
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament ELISA validation.
Petzold A; Altintas A; Andreoni L; Bartos A; Berthele A; Blankenstein MA; Buee L; Castellazzi M; Cepok S; Comabella M; Constantinescu CS; Deisenhammer F; Deniz G; Erten G; Espiño M; Fainardi E; Franciotta D; Freedman MS; Giedraitis V; Gilhus NE; Giovannoni G; Glabinski A; Grieb P; Hartung HP; Hemmer B; Herukka SK; Hintzen R; Ingelsson M; Jackson S; Jacobsen S; Jafari N; Jalosinski M; Jarius S; Kapaki E; Kieseier BC; Koel-Simmelink MJ; Kornhuber J; Kuhle J; Kurzepa J; Lalive PH; Lannfelt L; Lehmensiek V; Lewczuk P; Livrea P; Marnetto F; Martino D; Menge T; Norgren N; Papuć E; Paraskevas GP; Pirttilä T; Rajda C; Rejdak K; Ricny J; Ripova D; Rosengren L; Ruggieri M; Schraen S; Shaw G; Sindic C; Siva A; Stigbrand T; Stonebridge I; Topcular B; Trojano M; Tumani H; Twaalfhoven HA; Vécsei L; Van Pesch V; Vanderstichele H; Vedeler C; Verbeek MM; Villar LM; Weissert R; Wildemann B; Yang C; Yao K; Teunissen CE
J Immunol Methods; 2010 Jan; 352(1-2):23-31. PubMed ID: 19857497
[TBL] [Abstract][Full Text] [Related]
11. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
[TBL] [Abstract][Full Text] [Related]
12. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.
Schadendorf D; Amonkar MM; Milhem M; Grotzinger K; Demidov LV; Rutkowski P; Garbe C; Dummer R; Hassel JC; Wolter P; Mohr P; Trefzer U; Lefeuvre-Plesse C; Rutten A; Steven N; Ullenhag G; Sherman L; Wu FS; Patel K; Casey M; Robert C
Ann Oncol; 2014 Mar; 25(3):700-706. PubMed ID: 24504441
[TBL] [Abstract][Full Text] [Related]
13. Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.
Weber MS; Prod'homme T; Youssef S; Dunn SE; Steinman L; Zamvil SS
J Neuroinflammation; 2014 Feb; 11():29. PubMed ID: 24498870
[TBL] [Abstract][Full Text] [Related]
14. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
; Beecham AH; Patsopoulos NA; Xifara DK; Davis MF; Kemppinen A; Cotsapas C; Shah TS; Spencer C; Booth D; Goris A; Oturai A; Saarela J; Fontaine B; Hemmer B; Martin C; Zipp F; D'Alfonso S; Martinelli-Boneschi F; Taylor B; Harbo HF; Kockum I; Hillert J; Olsson T; Ban M; Oksenberg JR; Hintzen R; Barcellos LF; ; ; Agliardi C; Alfredsson L; Alizadeh M; Anderson C; Andrews R; Søndergaard HB; Baker A; Band G; Baranzini SE; Barizzone N; Barrett J; Bellenguez C; Bergamaschi L; Bernardinelli L; Berthele A; Biberacher V; Binder TM; Blackburn H; Bomfim IL; Brambilla P; Broadley S; Brochet B; Brundin L; Buck D; Butzkueven H; Caillier SJ; Camu W; Carpentier W; Cavalla P; Celius EG; Coman I; Comi G; Corrado L; Cosemans L; Cournu-Rebeix I; Cree BA; Cusi D; Damotte V; Defer G; Delgado SR; Deloukas P; di Sapio A; Dilthey AT; Donnelly P; Dubois B; Duddy M; Edkins S; Elovaara I; Esposito F; Evangelou N; Fiddes B; Field J; Franke A; Freeman C; Frohlich IY; Galimberti D; Gieger C; Gourraud PA; Graetz C; Graham A; Grummel V; Guaschino C; Hadjixenofontos A; Hakonarson H; Halfpenny C; Hall G; Hall P; Hamsten A; Harley J; Harrower T; Hawkins C; Hellenthal G; Hillier C; Hobart J; Hoshi M; Hunt SE; Jagodic M; Jelčić I; Jochim A; Kendall B; Kermode A; Kilpatrick T; Koivisto K; Konidari I; Korn T; Kronsbein H; Langford C; Larsson M; Lathrop M; Lebrun-Frenay C; Lechner-Scott J; Lee MH; Leone MA; Leppä V; Liberatore G; Lie BA; Lill CM; Lindén M; Link J; Luessi F; Lycke J; Macciardi F; Männistö S; Manrique CP; Martin R; Martinelli V; Mason D; Mazibrada G; McCabe C; Mero IL; Mescheriakova J; Moutsianas L; Myhr KM; Nagels G; Nicholas R; Nilsson P; Piehl F; Pirinen M; Price SE; Quach H; Reunanen M; Robberecht W; Robertson NP; Rodegher M; Rog D; Salvetti M; Schnetz-Boutaud NC; Sellebjerg F; Selter RC; Schaefer C; Shaunak S; Shen L; Shields S; Siffrin V; Slee M; Sorensen PS; Sorosina M; Sospedra M; Spurkland A; Strange A; Sundqvist E; Thijs V; Thorpe J; Ticca A; Tienari P; van Duijn C; Visser EM; Vucic S; Westerlind H; Wiley JS; Wilkins A; Wilson JF; Winkelmann J; Zajicek J; Zindler E; Haines JL; Pericak-Vance MA; Ivinson AJ; Stewart G; Hafler D; Hauser SL; Compston A; McVean G; De Jager P; Sawcer SJ; McCauley JL
Nat Genet; 2013 Nov; 45(11):1353-60. PubMed ID: 24076602
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic decisions in multiple sclerosis: moving beyond efficacy.
Brück W; Gold R; Lund BT; Oreja-Guevara C; Prat A; Spencer CM; Steinman L; Tintoré M; Vollmer TL; Weber MS; Weiner LP; Ziemssen T; Zamvil SS
JAMA Neurol; 2013 Oct; 70(10):1315-24. PubMed ID: 23921521
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
Degen A; Weichenthal M; Ugurel S; Trefzer U; Kilian K; Garbe C; Egberts F; Poppe LM; Hauschild A; Gutzmer R
J Dtsch Dermatol Ges; 2013 Sep; 11(9):846-53. PubMed ID: 23879405
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Ribas A; Kefford R; Marshall MA; Punt CJ; Haanen JB; Marmol M; Garbe C; Gogas H; Schachter J; Linette G; Lorigan P; Kendra KL; Maio M; Trefzer U; Smylie M; McArthur GA; Dreno B; Nathan PD; Mackiewicz J; Kirkwood JM; Gomez-Navarro J; Huang B; Pavlov D; Hauschild A
J Clin Oncol; 2013 Feb; 31(5):616-22. PubMed ID: 23295794
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.
Waubant E; Pelletier D; Mass M; Cohen JA; Kita M; Cross A; Bar-Or A; Vollmer T; Racke M; Stüve O; Schwid S; Goodman A; Kachuck N; Preiningerova J; Weinstock-Guttman B; Calabresi PA; Miller A; Mokhtarani M; Iklé D; Murphy S; Kopetskie H; Ding L; Rosenberg E; Spencer C; Zamvil SS; ;
Neurology; 2012 Apr; 78(15):1171-8. PubMed ID: 22459680
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Patsopoulos NA; ; ; ; ; ; Esposito F; Reischl J; Lehr S; Bauer D; Heubach J; Sandbrink R; Pohl C; Edan G; Kappos L; Miller D; Montalbán J; Polman CH; Freedman MS; Hartung HP; Arnason BG; Comi G; Cook S; Filippi M; Goodin DS; Jeffery D; O'Connor P; Ebers GC; Langdon D; Reder AT; Traboulsee A; Zipp F; Schimrigk S; Hillert J; Bahlo M; Booth DR; Broadley S; Brown MA; Browning BL; Browning SR; Butzkueven H; Carroll WM; Chapman C; Foote SJ; Griffiths L; Kermode AG; Kilpatrick TJ; Lechner-Scott J; Marriott M; Mason D; Moscato P; Heard RN; Pender MP; Perreau VM; Perera D; Rubio JP; Scott RJ; Slee M; Stankovich J; Stewart GJ; Taylor BV; Tubridy N; Willoughby E; Wiley J; Matthews P; Boneschi FM; Compston A; Haines J; Hauser SL; McCauley J; Ivinson A; Oksenberg JR; Pericak-Vance M; Sawcer SJ; De Jager PL; Hafler DA; de Bakker PI
Ann Neurol; 2011 Dec; 70(6):897-912. PubMed ID: 22190364
[TBL] [Abstract][Full Text] [Related]
20. Defining the critical hurdles in cancer immunotherapy.
Fox BA; Schendel DJ; Butterfield LH; Aamdal S; Allison JP; Ascierto PA; Atkins MB; Bartunkova J; Bergmann L; Berinstein N; Bonorino CC; Borden E; Bramson JL; Britten CM; Cao X; Carson WE; Chang AE; Characiejus D; Choudhury AR; Coukos G; de Gruijl T; Dillman RO; Dolstra H; Dranoff G; Durrant LG; Finke JH; Galon J; Gollob JA; Gouttefangeas C; Grizzi F; Guida M; Håkansson L; Hege K; Herberman RB; Hodi FS; Hoos A; Huber C; Hwu P; Imai K; Jaffee EM; Janetzki S; June CH; Kalinski P; Kaufman HL; Kawakami K; Kawakami Y; Keilholtz U; Khleif SN; Kiessling R; Kotlan B; Kroemer G; Lapointe R; Levitsky HI; Lotze MT; Maccalli C; Maio M; Marschner JP; Mastrangelo MJ; Masucci G; Melero I; Melief C; Murphy WJ; Nelson B; Nicolini A; Nishimura MI; Odunsi K; Ohashi PS; O'Donnell-Tormey J; Old LJ; Ottensmeier C; Papamichail M; Parmiani G; Pawelec G; Proietti E; Qin S; Rees R; Ribas A; Ridolfi R; Ritter G; Rivoltini L; Romero PJ; Salem ML; Scheper RJ; Seliger B; Sharma P; Shiku H; Singh-Jasuja H; Song W; Straten PT; Tahara H; Tian Z; van Der Burg SH; von Hoegen P; Wang E; Welters MJ; Winter H; Withington T; Wolchok JD; Xiao W; Zitvogel L; Zwierzina H; Marincola FM; Gajewski TF; Wigginton JM; Disis ML
J Transl Med; 2011 Dec; 9():214. PubMed ID: 22168571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
